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Background: New treatment modalities are needed for the treatment of cancers of the head and neck region
(HNSCC). Survivin is important for the survival and proliferation of tumor cells and may therefore provide a target
for immunotherapy. Here we focused on the ex vivo presence and in vitro induction of survivin specific T cells.
Methods: Tetramer staining and ELIspot assays were used to document the presence of survivin specific T cells in
patient derived material, and to monitor the presence and persistence of survivin specific T cells after repeated
in vitro stimulation with autologous dendritic cells.
Results: Ex vivo analysis showed the presence of survivin-specific T cells in the peripheral blood (by tetramer
analysis) and in the draining lymph node (by ELIspot analysis) in a HNSCC and a locally advanced breast cancer
patient respectively. However, we were unable to maintain isolated survivin specific T cells for prolonged periods of
time. For the in vitro generation of survivin specific T cells, monocyte derived DC were electroporated with mRNA
encoding full length survivin or a survivin mini-gene together with either IL21 or IL12 mRNA. Western blotting and
immunohistochemical staining of dendritic cell cytospin preparations confirmed translation of the full length
survivin protein. After repeated stimulation we observed an increase, followed by a decrease, of the number of
survivin specific T cells. FACS sorted or limiting dilution cloned survivin specific T cells could not be maintained on
feeder mix for prolonged periods of time. Protein expression analysis subsequently showed that activated, but not
resting T cells contain survivin protein.
Conclusions: Here we have shown that survivin specific T cells can be detected ex vivo in patient derived material.
Furthermore, survivin specific T cells can be induced in vitro using autologous dendritic cells with enforced expression
of survivin and cytokines. However, we were unable to maintain enriched or cloned survivin specific T cells for
prolonged periods of time. Endogenous expression of survivin in activated T cells and subsequent fratricide killing
might explain our in vitro observations. We therefore conclude that survivin, although it is a universal tumor antigen,
might not be the ideal target for immunotherapeutic strategies for the treatment of cancer of the head and neck.
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Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world [1,2]. In the
past decades there has been little improvement in the
survival rate of HNSCC patients, which is relatively low.
Therefore, the development of novel therapies is important.
An attractive therapeutic option is immunotherapy, which
can be implemented after standard treatment like surgery,
radiotherapy or chemotherapy [3-5].
Tumor specific T cells can recognize and kill tumor
cells either directly or through the production of cytokines.
Dendritic cells loaded with tumor antigens can stimulate T
cells leading to T cell activation and expansion. Ideally,
tumor associated antigens (TAA) are specific for tumor
cells, however, most tumor antigens are also expressed in
normal tissues albeit often at lower levels. In a number of
cases tumor antigens are derived from proteins that
promote transformation and tumor genesis and may
even be required to maintain a malignant phenotype [6].
Examples of well-known tumor antigens expressed in
HNSCC are p53, Mage-A3, Her2/neu and survivin [7-10].
Survivin is an inhibitor of apoptosis and involved in mitotic
spindle formation [11,12]. Survivin is highly expressed in
most cancers, but only to a small extent in normal tissue
[13]. In normal cells it is expressed in a cell-cycle dependent
matter, i.e. only during mitosis, after which it is rapidly
degraded [14]. Survivin is a protein that is important
for the tumor’s survival and proliferation, and therefore an
interesting TAA candidate. Survivin expression in malig-
nant tumors has been associated with poor prognosis [15].
Five splice variants of survivin have been identified:
full length or wild type (wt) survivin, survivin 2B, 3B,
Dex3 and 2alpha. Survivin wt, 2B and 3B are expressed
in the cytoplasm, Dex3 in the nucleus and 2A in the
cytoplasm and nucleus. Like survivin wild type, the
splice variant Dex3 appears to be anti-apoptotic [16],
whereas survivin 2A and 2B may be pro-apoptotic
[17-19]. In oropharyngeal tumors and upper urinary
tract urothelial carcinoma, nuclear expression of survivin
is associated with a poor prognosis [20,21].
In healthy donors survivin specific T cell frequencies
in the peripheral blood are often very low, if not
undetectable [22]. In cancer patients somewhat higher
percentages of survivin specific T cells can be detected
in peripheral blood [22]. Survivin specific T cells have
been found in several types of tumors, like breast cancer,
leukemia, colorectal cancer and melanoma patients
[23-28]. According to Weide et al. the absence of
survivin specific T cell reactivity in the blood of patients
with distant melanoma metastasis is a poor predictor of
overall survival, whereas the presence of NY-ESO and
Mage-3 specific T cells is a good predictor [29].
In murine models survivin vaccination has been shown
to eradicate tumors by inducing survivin specific CD8+ Tcells [30-33]. Zeis et al. demonstrated that by using survivin
mRNA transfected dendritic cells (DC) to vaccinate mice,
long term resistance to lymphoma challenge was obtained.
Subsequently they showed that survivin specific T cells
were capable of killing tumor cell lines [30], indicating that
survivin is immunogenic and could be a useful target for
immunotherapeutic strategies.
Moderate results have been reported in phase I/II
trials where cancer patients have been vaccinated with
synthetic survivin peptides [34-37]. In a phase I trial,
myeloma patients received autografts followed by
ex vivo anti-CD3/anti-CD28 co-stimulated autologous
T cells at day 2 after transplantation. Half of the
patients additionally received hTERT and survivin
peptide immunizations resulting in increased survival
compared to the group that did not receive additional
vaccination [34]. Unfortunately no distinction was
made in the tetramer readout system between
survivin and hTERT, therefore the role of survivin in
the patients immune response remains unclear. Data
obtained from a phase-II peptide vaccination trial in
metastatic melanoma showed that survivin-specific T
reactivity in about one fifth of the patients correlated
with increased overall survival [36]. In a phase I trial
the splice variant survivin 2B peptide has been used
in HLA-A24 positive patients with oral cancer.
Although the response rate was low (one partial
responder and nine patients with progressive disease),
an increase in survivin specific T cells was observed
after vaccination [35].
Here we document the presence of survivin specific T
cells in patient derived peripheral blood and lymph
nodes and report on our efforts to induce and maintain
survivin specific T cells, employing CD8+ T cells and
autologous dendritic cells transfected with mRNA




Peripheral blood from five HLA-A2 positive HNSCC
patients was used to monitor the presence of survivin
specific T cells. The HNSCC patients were treated at the
VU University Medical Center in Amsterdam, the
Netherlands with surgery, chemotherapy, radiotherapy
or a combination of these. Blood was drawn at least
six weeks after the last treatment via a vena puncture.
All patients signed an informed consent form,
approved by the Institutional Review Board (METc-VUmc
registrationnumber:2009/205). Lymph node derived T
cells from a patient suffering from locally advanced breast
cancer was used to determine TAA specific T cells by
ELIspot. The patient took part in a IRB-approved clinical
trial where she received 6 neoadjuvant chemotherapy cycles
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DNA vectors and in vitro transcription of mRNA
Multiple survivin constructs were designed, the survivin
inserts were codon modified and generated by Geneart
(Regensburg, Germany) and cloned into pGEM4Z
vectors (kindly provided by dr. Viggo van Tendeloo,
Antwerp, Belgium). The mini-survivin sequence (including
the immunodominant HLA-A2 binding T cell epitope) was
cloned into pGEM as an EcoRI-NotI fragment, resulting in
pGEM-mini-survivin (mini-survivin in short for the




The Ubi-mini-survivin sequence was cloned into
pGEM as an XhoI-NotI fragment, resulting in pGEM-
Ubi-mini-survivin (Ubi-mini-survivin in short for the






immunodominant HLA-A2 binding T cell epitope
survivin(96–104) is indicated in bold in both sequences.
The survivin(96–104 epitope is located in the 3rd exon of
survivin and is therefore present in wild type survivin and
the splice variants 2B and 3B, but absent in survivin splice
variants 2alpha and Dex3.
Two full length survivin wild type constructs were
used (pGEM-survivin and pGEM-Ubi-survivin along
the lines described above. A codon-modified minigene
(Ubi-mini-MART for the mRNA) containing four
repeats of the altered peptide ligand ELAGIGILTV
(was used as described before [38]). In vitro transcription
was carried out according to manufacturer’s protocol of
the T7 mMessage-mMachine kit (Ambion, Huntingdon,
Cambridgeshire, UK) to generate m7G(50)pppGcapped
IVT mRNA (CAP). mRNA quality was checked by agarose
gel electrophoresis. RNA concentration was assayed by
spectrophotometrical analysis at OD260.
Dendritic cell generation and phenotype analysis
Healthy donor derived peripheral blood mononuclear cells
(PBMC) were isolated from HLA-A2 positive buffycoats
(Sanquin, Amsterdam, The Netherlands) by density
gradient centrifugation using Lymphoprep (Nycomed,
Oslo, Norway). Monocytes were isolated by positive
selection using a MACS column (MACS; Miltenyi
Biotec, Bergisch Gladbach, Germany). PBMCs were
labeled with anti-CD14 beads (Miltenyi Biotec) followed
by MACS sorting according to the manufacturer’sprotocols. Subsequently, the monocytes were cultured
with 100 ng/mL recombinant human granulocyte colony
stimulating factor (rhGM-CSF; Sagramostim, Berlex) and
10 ng/mL interleukin 4 (IL4; R&D systems) for 6 to 7 days
in IMDM medium supplemented with 8% fetal calf serum
(FCS; HyClone), 2 mM L-glutamine and antibiotics
(100 IE/ml penicillin and 100 μg/mL streptomycin, life
technologies). The immature DCs were then matured by
culturing them with monocyte conditioned medium
(MCM) 25% v/v (generated as previously described
[39]) and 50 ng/mL tumor necrosis factor (TNF)α
(Miltenyi Biotec). DCs were analyzed phenotypically
to determine the maturation status using flow cytometry.
The following antibodies were used for phenotypic analysis:
IgG1, CD14, CD80, CD83, HLA-DR (BD Biosciences,
Heidelberg, Germany), CD1a, CD86, CD40 (Pharmingen,
San Diego, CA, USA) labeled with Phycoerythrin
(PE). Mean fluorescence index was calculated as follows:
MFI-Index = (mean fluorescence intensity marker)/
(fluorescence intensity isotype).
Preparation of dendritic cells for the detection of survivin
in western blot and cytospins
Mature DC were electroporated [40] with eGFP,
Ubi-survivin or survivin mRNA. Cells were electroporated
with 10 μg mRNA in 200 μL electrobuffer (Cell Projects
Ltd) in 4 mm cuvets (Cell Projects Ltd) at 300 Volt and
150 μF (Easyject plus, Equibio, Kent, UK). One hour
after electroporation cells were washed and plated out
in 1*106/mL IMDM medium supplemented with 8%
fetal calf serum (FCS; HyClone), 2 mM L-glutamine
and antibiotics (100 IE/ml penicillin and 100 μg/mL
streptomycin, life technologies).
For Western blot, 4 hours after electroporation
with mRNA encoding either eGFP, survivin or Ubi-
survivin 1*106 cells were harvested and washed with
phosphate-buffered saline (PBS). DC were harvested
for cytospin preparations, at time points 2, 4, 6, and
24 hours after electroporation with RNA encoding either
eGFP, survivin or Ubi-survivin.
T cell activation and survivin protein detection
Isolation of resting CD8β positive T cells from HLA-A2
positive, healthy donor PBMC (Sanquin) was performed
by positive selection using a MACS column (Miltenyi
Biotec). For this purpose, total PBL were incubated with
anti-CD8β mAb (clone: 2ST8.5H7, Beckman Coulter, Inc.)
and subsequently with microbead-conjugated anti-mouse
IgG Abs (Miltenyi Biotec), followed by MACS sorting
according to the manufacturer’s protocol. Per donor
6*106 CD8β + T cells were cultured in Yssels medium
supplemented with 1% hAB in order to obtain resting T
cells. Another aliquot of CD8β + T cells were cultured in
the presence of 100 U/mL IL2 and 500 ng/mL PHA in
Turksma et al. Journal of Translational Medicine 2013, 11:152 Page 4 of 13
http://www.translational-medicine.com/content/11/1/152order to obtain activated T cells. After a 48 hour
incubation period, the T cells were harvested for
FACS and Western blot analysis. T cell activation
levels were determined by incubating the T cells with
anti-CD25 PE and CD69 FITc (BD Biosciences). Cells
were subsequently measured by flow cytometry.
Western blot analysis
Cell pellets were resuspended in lysis buffer (50 mmol/l
Tris/HCl, pH 8.0, 0.5% NP-40, 5 mmol/l EDTA)
containing protease inhibitors. Protein levels in the samples
were quantified according to manufacturer’s protocol using
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
USA). Expression of survivin was detected using a 1:1000
dilution of rabbit-anti-survivin (clone 71G4B7, Cell
Signaling Technology, Inc, Boston, USA), followed by
incubation with a 1:1000 dilution of polyclonal swine-
anti-rabbit immunoglobulin/HRP (DakoCytomation,
Glostrup, Denmark). Proteins were visualized with the
enhanced chemo-luminescence technique (Amersham
Pharmacia Biotech, Piscataway, NJ, USA).
Cytospins
Cytospin samples of dendritic cells were prepared as
followed; per condition 20.000 cells were taken up in
100 uL PBS and spun down for 3 minutes at 600 rpm on a
Superfrost plus slide (Thermo Scientific, Braunschweig,
Germany). Cytospins were next air dried overnight, fixed in
acetone for 10 minutes and stained with anti-survivin(clone
71G4B7, Cell Signalling Technology, Inc.). According to the
manufacturer this rabbit mAb was produced by immuniz-
ing animals with a synthetic peptide corresponding to
residues surrounding cysteine 60 of human survivin and
detects endogenous levels of total survivin protein.
Induction of survivin specific CD8+ T cells and detection
by tetramer binding
Isolation of resting CD8β positive T cells from healthy
donor PBMC (Sanquin) was performed by positive
selection using a MACS column (Miltenyi Biotec).
For this purpose, total PBL were incubated with anti-CD8β
mAb (clone: 2ST8.5H7, Beckman Coulter, Inc., Marseille,
France) and subsequently with microbead-conjugated
anti-mouse IgG Abs (Miltenyi Biotec), followed by
MACS sorting according to the manufacturer’s protocol.
Mature DC were electroporated with survivin mRNA in
combination with IL12 mRNA or IL21 mRNA as
described above. One hour after electroporation DCs were
washed and multiple mini-cultures containing 0.5–1 ×106
CD8β T cells, 0.5–1 ×105 mRNA-transfected DCs and
0.25–0.5 ×106 irradiated autologous CD4+ T cells were set
up in Yssel’s medium supplemented with 1% hAB and
10 U/mL IL7. After 10 days, T cells were analyzed for
specificity using PE- and/or APC-labeled HLA-A*0201tetramers (Tm) presenting the survivin 5, 95, 96 or
96 M epitope (survivin 5–14: TLPPAWQPF, survivin
95–104: ELTLGEFLKL, survivin 96–104: LTLGEFLKL,
survivin 96 M: LMLGEFLKL). We have used in-house
prepared tetramers, which at that moment in time
could not be tested for specific binding since bona
fide survivin specific T cell clones were unavailable to
us. In a similar case in the past we have validated HPV
specific tetramers by using two different fluorescent dyes
[41], thus excluding non-specific binding of one of the
tetramers. Staining was performed in PBS supplemented
with 0.1% BSA and 0.01% Sodium azide for 15 min at
37°C. On day 10 the bulk cultures were re-stimulated
with mRNA electroporated DCs and the next day 20 U/
mL IL2 (R&D systems, Oxon, UK) was added. Tetramer
staining was performed after 7 days and the bulk cultures
were re-stimulated weekly as described above.
ELIspot assay to measure cellular production of IFN- γ
Tumor-draining lymph node material, from patients
suffering from locally advanced breast cancer, was used
to determine the presence of survivin specific T cells.
Antigen-induced interferon gamma (IFN-γ) secretion
by survivin induced T cells was measured by an
EnzymeLinked Immuno-spot (ELIspot) assay using a
modification of a described technique [42]. After wells
of nitrocellulose-bottom 96-well plates (MultiScreen-HA;
Millipore, Billerica, MA) were coated overnight with 50 μL
monoclonal anti-IFN-γ antibody (10 μg/mL; R&D Systems,
Minneapolis, MN), the plates were washed, 1% bovine
serum albumin was added to each well to block
nonspecific binding, and the plates were washed again.
The survivin long peptides shown in Additional file 1:
Figure S1C were used to load target cells (autologous
moDCs). DCs alone or with the survivin long peptides
(5 μM) were added in a total volume of 100 μL of complete
RPMI medium to the wells and incubated at room
temperature for 1 h. The CD4+ or CD8+ T cells were
added (1 × 104 cells/well) in 100 μL of complete RPMI
medium with added IL2 (20 U/mL) and incubated for 48 h
at 37°C with the target cells (1 × 103 cells per well). After
the plates were washed, captured IFN-γ was detected by
incubation with 50 μL of biotin-conjugated goat anti-
human IFN-γ (R&D systems) for 2 h at 37°C in the
dark, and the plates were rewashed, incubated for 1 h at
37°C with streptavidin-alkaline phosphatase (Zymed, San
Francisco, CA) diluted 1:10.000 in conjugate buffer (1%
bovine serum albumin in PBS plus 0.05% Tween 20),
washed, and incubated with 50 μL of FAST 5-bromo-4-
chloro-3-indolylphosphate nitroblue tetrazolium (BCIP/
NBT) substrate (Sigma) for 30 min at 37°C in the dark.
After drying the plates overnight in the dark, spot-forming
cells (SFC) corresponding to individual IFN-γ-secreting
cells were counted using an AID ELISPOT reader
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The background number of SFC was determined by
incubating the CD8+ cells with autologous moDCs
alone or autologous moDCs loaded with irrelevant peptide
(HPV long peptide), and wells containing CD8+ T cells
were included as a negative control. Each determination
was performed in duplicate, and the results were expressed
as SFC/number of plated CD8+ T cells.
Results
Survivin specific CD8 positive T cells in peripheral blood
and lymph nodes from cancer patients
We measured the percentage of survivin specific T cells in
PBMC derived from the peripheral blood of five patients
with head and neck cancer. In three of these patients we
found T cells binding HLA-A2 tetramers containing the
survivin derived epitope TLPPAWQPFL (Survivin 5–14)
(Figure 1A). For one of the patients T cell numbers enabled
us to FACS sort the tetramer positive population and clone
them by limiting dilution cloning (0.2 cell/well). In 3 out of
20 wells with growing T cells we detected 20-27% survivin
specific T cells. A representative example of one of these
cultures is given in Figure 1B. However, these three
cultures fared poorly (scatter plot shown in Figure 1) and
could not be maintained for prolonged periods of
time, thus precluding functional analysis, e.g. cytokine
production or tumor cell recognition and killing.
In a tumor-draining lymph node obtained from
another patient, in this case suffering from locally
advanced breast cancer and treated with six cycles of
neo-adjuvant chemotherapy, we detected tumor antigen
associated specific T cells. The spontaneously arising T
cells were tested in an interferon-gamma ELIspot assay
against a number of different nine-mer HLA-A2-binding
peptides representing tumor associated CTL epitopes;
Survivin-95, CEA-571, Her-2/Neu-369 and Her-2/
Neu-654. As a negative control we used the virally
derived HPV16E7(11–20) peptide. Indicated are the
number of spots per 100.000 T cells. The results given
in Figure 1C clearly shows survivin specific reactivity
amongst reactivity against other TAA.
Having established that spontaneously arising survivin
specific T cells can be detected in cancer patients we
embarked on in vitro induction experiments using
healthy donor derived mature DC, electroporated with
in vitro transcribed mRNA, as stimulator cells and isolated
CD8+ T cells as responders, the purpose being to
optimize T cell stimulation protocols, employing mature
DC, survivin and cytokine encoding mRNA, for in vivo
vaccination studies in HNSCC cancer patients.
DNA constructs encoding survivin
For the production of in vitro transcribed mRNA we
designed a number of pGEM constructs encoding eitherfull length survivin or mini-gene constructs containing T
cell epitopes derived thereof. A survivin mini-gene
construct containing four codon modified repeats of
survivin95-107 was prepared as described previously for a
different TAA (Mart-1/MelanA) [38]. DC need to process
the immunodominant T cell epitope (survivin96-104)
from this repeat and present it in the context of HLA-A2.
In a number of constructs survivin or the mini-gene
repeats were preceded by Ubiquitin sequences to enhance
degradation through the proteasome resulting in
enhanced MHC class I presentation. An overview of
the different constructs, is shown in Figure 2.Detection of survivin protein in transfected cells
Next we tested for the presence of survivin protein in
transfected cells. Monocyte derived dendritic cells were
electroporated with mRNA encoding either GFP as a
control, or full length survivin either or not preceded by
Ubiquitin sequences. Lysates of cells were prepared four
hours after electroporation of mRNA. Western blot
analysis showed a clear band for survivin protein, of the
expected molecular weight of 16.3 kD, in mature DC
electroporated with full length survivin mRNA (Figure 3A,
lane 2), but not in control GFP electroporated DC
(Figure 3A, lane 1). As expected no specific protein
band for survivin was found in the lysate of DC after
electroporation with Ubi-survivin mRNA (Figure 3A,
lane 3). Staining of high molecular weight protein
bands was observed in all three lanes.
Next we determined survivin expression in mature DC
by immunohistochemical staining of cytospin preparations
(Figure 3B). Cytospins were prepared at 2, 4, 6, 8 and
24 hours after electroporation of mature DC. Low level
survivin staining was seen in GFP and in Ubi-survivin
electroporated DC at all time points included in the
analysis. Staining of survivin protein was most prominent
in cytospins taken at 4 h and 6 h after electroporation of
mature DC with full length survivin encoding mRNA.
Specific staining was reduced to background level in these
cells taken at time point 24 h. From these experiments we
concluded that the full length survivin sequence, used in
two of the DNA constructs shown in Figure 2, is capable
of driving the production of survivin protein.Induction of antigen specific CD8 positive T cells from
healthy donors
Next to the induction of survivin specific T cells we
applied our protocols to the induction of Influenza
specific (memory) T cells using peptide loaded mature
DC, and Mart-1 specific (naive) T cells using mRNA
electroporated mature DC [38,41]. CD8+ T cells and
monocyte derived mature DC from an HLA-A2 positive
healthy donor were used.
AC
B
Figure 1 Spontaneously arising survivin specific T cells in patients. A) Direct ex vivo tetramer staining of T cells derived from HNSCC
patients. The patients (1 thru 5) were all HLA-A2 positive and the CD8 positive T cells were stained with HLA-A2 tetramers containing either the
survivin 5 (light grey bars), survivin 96 (dark grey bars) or the modified survivin 96M (black bars) epitope. The percentage tetramer positive T cells
in incidated on the Y-axis. B) PBMC from HNSCC patients were stained with HLA-A2 tetramers containing the survivin 5 epitope and
subsequently sorted by flow cytometry. Cells were plated out at a concentration of 0.2 cells per well and stimulated with feeder mix weekly. The
left hand panel shows the forward scatter (X-axis; FSC) and side scatter (Y-axis; SSC) of the cells after four weeks of stimulation with feeder mix. A
boxed live gate is indicated. The right hand panel shows tetramer staining of the cells in the live gates. Survivin 5 tetramer labeled with either
APC (X-axis) or PE (Y-axis) were used to stain the T cells. The percentage of double tetramer positive cells is shown in the upper right quadrant.
C) Draining lymph nodes were obtained from a patient with locally advanced breast cancer, who had received neo-adjuvant chemotherapy
before surgery. The spontaneously arising T cells were tested in an ELIspot assay against a number of different HLA-A2 binding peptides
representing CTL epitopes; Survivin(95–104), CEA(571–579), Her-2/Neu(369–377) and Her-2/Neu(654–662) respectively and HPV16E7-(11–20)
peptide as a negative control. Indicated are the number of spots per 100.000 T cells.
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peptide loaded (Influenza) or mRNA electroporated
(Mart-1) mature DC we tested T cell bulk cultures for
the presence of specific T cells employing tetramers.
High percentages of specific T cells for Influenza (7%
tetramer positive) and Mart-1 (19% tetramer positive)
were detected after as little as two in vitro stimulations
(Figure 4A). In this particular donor the percentage of
survivin specific T cells remained below the detection
limit. Influenza or Mart-1 specific T cells can be enriched







Figure 2 pGEM constructs containing survivin. The DNA vector pGEM w
bars indicate the survivin sequence, either full length or the 95–104 sequencloning. Importantly such T cell clones or cultures can be
maintained in culture, using feeder mix stimulations, at
near hundred percent purity for prolonged periods of time
without loss of specificity or reactivity (data not shown
and data published by us previously [38,41,43-45]).
Next we stimulated T cells with mature DC co-
electroporated with full length survivin mRNA and IL21
mRNA. After as many as five in vitro stimulations we
detected low levels of survivin specific T cells staining
with tetramers containing either the wild type (0.2%
positive for survivin(96–104) or M-modified survivinsurvivin
survivin
s95 s95 s95s95
s95 s95 s95 s95
as used as a template for four different survivin constructs. The green
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Figure 3 Survivin expression after electroporation of mRNA in mature dendritic cells. A) Mature monocyte derived dendritic cells were
electroporated with mRNA encoding eGFP, full length survivin or full length Ubi-survivin. Four hours after electroporation the DCs were harvested
and lysed. Samples contained equal amounts of cellular protein. The arrow indicates a protein band of 16.3 kD, the predicted molecular weight
of full length survivin. B) Cytospin preparation were obtained from mature monocyte derived dendritic cells electroporated with mRNA encoding
either eGFP (upper panel), full length survivin (middle panel) or full length Ubi-survivin (lower panel). After 2, 4, 6, 8 and 24 hours the
electroporated DCs were harvested, spun down on a glass slide and stained with anti-survivin antibodies. Brown staining indicates survivin
protein. Nuclei appear in blue.

































































Figure 4 Tetramer staining after T cell induction. A) CD8+ T cells from donor 1, were stimulated twice with autologous mature DC
loaded with either Influenza peptide or electroporated with mRNA encoding Ubi-Mart4. The T cells were stained with an irrelevant tetramer
(HPV E7 11), Influenza 58 and Mart-1 27 L in APC (X-axis) and PE (Y-axis). T cells plotted in the upper right quadrant were considered antigen
specific. B) CD8+ T cells from donor 2, were stimulated five times with autologous DC electroporated with mRNA encoding full length survivin.
The T cells were stained with an irrelevant tetramer (Her2/neu 369), survivin 96 and survivin 96 M in APC (X-axis) and PE (Y-axis). T cells plotted
in the upper right quadrant were considered antigen specific.
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Figure 4B. We noted interferon-γ production as measured
in an ELIspot assay upon incubation of T cells with
peptide loaded DC for this donor but not for a second
donor (see Additional file 1: Figure S1 and Additional file 2:
Table S1). After limiting dilution cloning, outgrowth of T
cells was found in 69 of 920 wells seeded with survivin
tetramer binding T cells obtained after FACS sorting. None
of these wells,however, contained viable survivin(96–104)
specific T cells.
We next sought to improve on the in vitro stimulation
of specific T cells by using mRNA encoding Ubi-survivin,
mini-survivin of Ubi-mini-survvin in combination with
mRNA encoding IL12. Figure 5 shows the results after
in vitro stimulation of T cells for three times with survivin/
IL12 DC, followed by one IVS with Ubi-survivin/IL12 DC.
The percentages of tetramer positive T cells are indicated
for each well for survivin(5–14) (Figure 5A) and survivin
(96–104) (Figure 5B) epitope (range 3-10% positive).
Tetramer positive T cells were next MACS-isolated and put
in culture on feeder mix. In contrast to our expectations
based on prior experience with other T cell specificities,
MACS enrichment of survivin specific T cells did not result
in a T cell bulk culture with a high percentage of survivin
specific T cells (Figure 5A and B right hand panel).
These results prompted us to perform more T cell
inductions and monitor the appearance and persistenceSurvivin 5





















































Figure 5 Detection and MACS enrichment of survivin specific CD8+ T
autologous DC electroporated with mRNA encoding full length survivin an
Ubi-survivin and IL12. The T cells were stained with survivin tetramers. Each
T cells were MACS sorted en stimulated with feeder-mix. Depicted in the m
representative well after fourth stimulation, just before MACS sorting. In the
cells is depicted after one week on feeder mix. A) panels left, middle and r
middle and right show the data obtained with the survivin 96 epitope.of survivin specific T cells more closely. We set up
separate mini-cultures of T cells from one donor and
stimulated them once with either mini-survivin/IL12 DC or
Ubi-mini-survivin/IL12 DC. Subsequent restimulations
were performed using B cells (JY), electroporated with
mRNA encoding either mini-survivin or Ubi-mini-survivin
in combination with mRNA encoding IL12. We set up 20
wells per condition, each indicated with a separate symbol
in Figure 6. Prior to in vitro stimulation, survivin specific T
cells were undetectable using HLA-A2-survivin(96–104)
tetramers (data not shown). From the data presented it is
clear that the number of tetramer binding T cells went up
after the 3rd and 4th in vitro stimulation and reached
a maximum after the 5th stimulation (range 1-5%
positive T cells) in conditions where we used IL12
mRNA in conjunction with either mini-survivin (Figure 6A)
or Ubi-mini-survivin (Figure 6B). After the 6th in vitro
stimulation the numbers went down, never to reach these
levels again.
Survivin protein expression in activated T cells
Fratricide by survivin specific T cells has been postulated
as a possible explanation for the disappearance of survivin
expressing T cells in culture. Endogenous expression of
survivin by T cells would be a prerequisite for fratricide to
take place in the experimental wells. In order to investigate
this, we isolated resting and prepared activated T cells from7 days after 4th 
stimulation





















cells. CD8+ T cells from donor 2, were stimulated three times with
d IL12. The fourth stimulation was performed with mRNA encoding
symbol represents a separate mini-culture. After four stimulations the
iddle panel is the percentage of survivin specific T cells of one
right hand panel the percentage of MACS sorted survivin specific T
ight show the data obtained with the survivin 5 epitope. B) panels left,
A B Ubi-Mini-survivin












































Figure 6 Induction of survivin specific T cells; appearance and persistence. CD8+ T cells from an HLA-A2 positive healthy donor (number 6)
were primed with autologous mature DC and re-stimulated with JY. Antigen presenting cells were electroporated with mRNA encoding Mini
survivin or mini Ubi-survivin. The percentages of survivin 96 tetramer positive T cells found after 3, 4, 5 or 6 rounds of stimulation with APCs
electroporated with mRNA encoding either mini-Survivin (panel A) or Ubi-mini-survivin (panel B) are indicated. Each symbol represents one
individual well. A) The data points analyzed did not follow a Gaussian distribution and were analysed using a Kruskal-Wallis test with a Dunn’s Multiple
Comparison Test. B) The data points analyzed followed a Gaussian distribution and were analyzed with a Repeated Measures ANOVA with a Tukey’s
Multiple Comparison Test. Statistical analysis was performed and shown as NS: not significant; * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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expression levels of the T cell activation marker CD25. As
expected CD25 expression was low or absent on resting T
cells (Figure 7A), whereas approximately 90% of the
activated T cells showed high expression levels of CD25
(Figure 7B). Similar data were obtained for another T cell
activation marker CD69 (data not shown). Resting and
activated T cells were next used to determine endogenous
survivin protein expression. From the Western blot data
shown in Figure 7C it is clear that activated T cells express
appreciable levels of survivin protein, whereas resting
T cells do not.
Discussion
In our efforts to improve treatment of patients with
HNSCC we embarked on the induction of T cell responses
against widely expressed tumor antigens. One such tumor
antigen is survivin which is expressed in almost all tumor
types, including HNSCC, and is essential for tumor
cell survival. Our laboratories have a substantial track
record with respect to the induction, isolation and
maintenance of human T cells. In the past we have
isolated T cells against a variety of tumor antigens,
amongst which Human Papilloma Virus, Mart-1, human
telomerase reverse transcriptase (hTERT), ErbB3-binding
protein-1 (Ebp1), carcinoembryonic antigen (CEA) and
Her-2/neu [41,43-52].
Here we have shown the presence of survivin specific
T cells in PBMC of an HNSCC patient by means of
tetramer staining (Figure 1A; binding of survivin(5–14):
TLPPAWQPF) and in the draining lymph node of a
patient with advanced breast cancer by means of
ELIspot (Figure 1B; recognition of native survivin95-104:
ELTLGEFLKL). It was noted that survivin specific T cells
derived from these patients could not be maintained
in vitro for prolonged periods of times, unlike almost allother T cell clones we obtained in the past. One could
argue that such survivin specific T cells may have become
senescent due to continuous in vivo stimulation by tumor
cells present in these patient, resulting in shortening of
the telomeric ends of the chromosomes and subsequent
clonal exhaustion. Due to low T cell numbers we could
not determine the length of the telomeric ends of the
chromosomes in these T cells.
This argument of telomere erosion, however, surely
does not hold for survivin specific T cells induced from
PBMC taken from healthy donor blood (results shown
in Figures 4, 5 and 6). Prior to in vitro stimulation, these
T cells were antigen inexperienced, naive, and therefore
will have had long telomeres. The results shown in
Figure 6 suggest that survivin specific T cells can only be
maintained when the percentage remains below a certain
level, which may vary per donor or activation status of
the T cells. Another example of this is shown in Figure 5,
where we found survivin specific T cells up to 10% of
the cells in the life gate of the FACS. However, when
these cells were enriched and activated via feeder mix,
the percentage of survivin specific T cells dropped
dramatically.
A number of research groups have documented the
existence of survivin specific T cells, in mice as well as
in man. Sorensen et al. published on the generation of
an HLA-A2 restricted, survivin(96–104) specific T cell
clone [53]. This T cell clone, derived from a breast
cancer patient, was able to kill peptide loaded T2-target
cells in an HLA-A2 restricted fashion. Moreover the T cell
clone was able to recognize and kill a series of HLA-A2
positive tumors cells in classical cytotoxicity assays. In
contrast to this, Leisegang et al. reported on the lack
of success in generating survivin specific T cell lines

























Resting CD8+ T cells Activated CD8+ T cellsA B
5% 91%
Figure 7 Protein expression levels of survivin in resting and activated CD8+ T cells. CD8+ T cells from three healthy donors were isolated
and cultured for 48 hours. Half of the T cells per donor were kept in culture medium (resting T cells), the other half were activated with PHA and
IL-2 (activated T cells). A) Representative FACS histogram of resting T cells stained for the activation marker CD25. About 5% of the plotted cells
are CD25 positive. B) Representative FACS histogram of activated T cells stained for the activation marker CD25. About 91% of the plotted cells
are CD25 positive. C) Western blot of resting (−) or activated (+) T cells from three different donors (A, B, C), stained with anti-survivin antibodies.
The arrow indicates survivin protein as a band of around 16.3 kD. Household β-actin protein staining was used as a loading control.
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short lived protein [54]. Endogenous expression of
survivin, detected by immunohistochemistry and/or
western blot analysis, has been documented in human T
cells derived from patients with Multiple Sclerosis or
Crohn’s disease [55,56]. Leisegang reported on high level
expression of survivin mRNA in activated T cells. Here
we have documented the presence of survivin protein in
activated CD8+ T cells, and absence thereof in resting T
cells (results shown in Figure 7). Since survivin is a
protein which is rapidly ubiquitinylated and degraded
[54], it would be reasonable to assume that survivin
derived protein fragments are also processed and
presented in MHC class I, thus making activated T cells
an unintended target for survivin specific T cells.
In a commentary, Aqui and Vonderheide pointed out
that endogenous expression of potential tumor antigens,
like survivin and telomerase, in activated T cells might
lead to fratricide killing of T cells [57]. No signs of fratricide
however were reported by Sorensen et al., nor did they
report on survivin mRNA or protein expression in T cells.
Possible explanations could be that their T cell clone
carried a mutation in the epitope of survivin(96–104)
thereby losing the ability to be presented, or it may
have displayed overall malfunctions in HLA-A2 antigen
expression, thereby escaping fratricide killing.Recently, Leisegang et al. showed that in vitro cultured,
T cell receptor transgenic, survivin(96–104) specific T cells
underwent fratricide in an HLA-A2 dependent manner
[58]. They used dendritic cells and T cells from HLA-A2
negative donors. DC were electroporated with mRNA
encoding full length survivin in combination with HLA-A2
for the induction of HLA-A2 restricted survivin specific T
cells. Resulting, HLA-A2 negative, T cells were capable of
killing HLA-A2, survivin double positive tumour cells.
Introduction of HLA-A2 restricted, survivin specific T cell
receptors into polyclonal HLA-A2 positive T cells led to
fratricide killing of neighboring T cells [58].
In our experiments we noted that survivin specific T cells
could not be maintained in culture for prolonged periods of
time. Although we were unable to check for fratricide
mediated killing of neighboring T cells, due to a lack of
sufficient T cell numbers, our findings can very well be
explained by the observations made by Leisegang et al. for
the immunodominant T cell epitope survivin(96–104).
Although speculative, we documented lack of T cell
outgrowth for the survivin(5–14) epitope (TLPPAWQPF)
shown in Figure 1 as well.
Fratricide amongst survivin specific CD8+ T cells has
now been documented [58]. It remains unclear whether
fratricide will also occur in CD4+ T cells on the basis of
survivin epitopes presented in MHC-class II [59,60]. A
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for survivin [16-19]. Whether all of these are expressed
in activated T cells remains to be elucidated. One could
envision that T cell reactivity directed against survivin
splice variants, expressed in tumor cells but not in T
cells, may still be useful in cancer immunotherapy
approaches [61,62]. This notion may be exemplified by
the HLA-A24 restricted survivin 2B epitope 80–88
generated by Takahasi and colleagues [63]. The isolation of
HNSCC tumor infiltrating T cells and the identification of
epitopes being recognized may offer new therapeutic
targets. Alternatively, clinical use of ex vivo expanded tumor
infiltrating T cells with a range of (unknown) specificities
may also provide a viable treatment option for HNSCC
patients [64]. Survivin as an immunotherapeutic target may
still be useful in DC based active immunotherapy, since
in vivo the percentages of survivin specific T cells will most
likely remain below the ‘fratricide threshold’. However for
adoptive transfer purposes the use of survivin specific T
cells is self-destructive and therefore not feasible.Additional files
Additional file 1: Figure S1. A-B) T cells stimulated with survivin/IL21-
DC from two donors were tested in an IFN-y ELIspot assay. Autologous
mature DC loaded with survivin overlapping long-peptides were used as
antigen presenting cells. The long peptides were pooled in four different
mixes; Mix A, B, C and D (details in Figure S1C). The number of spots against
the mixes A-D and of the irrelevant HPV long peptide are shown on the
Y-axis. On the X-axis the number of spots per well are indicated. A) The
number of INF-y spots for donor 2. B) The number of INF-y spots for donor 3.
C) The aminoacid sequence of full-length wild-type survivin is depicted.
The long-peptides grouped into mix A,B,C and D used in the ELIspot assay
are depicted underneath.
Additional file 2: Table S1. Overview of survivin specific T cell
inductions per donor. Shown are the mRNA constructs, the number of
CD8+ T cells, the antigen presenting cell (for initial priming and
subsequent restimulation), and the readout systems (tetramer and/or
ELIspot) used.
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